SCHEMBL1072933

SCHEMBL1072933

CCC(N)Nc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 5/20 0.50
CYP3A4 P08684 4/20 0.43
TSHR P16473 4/20 0.43
ALDH1A1 P00352 4/20 0.43
HSD17B10 Q99714 4/20 0.43
ALOX15 P16050 3/20 0.43
LMNA P02545 3/20 0.43
THRB P10828 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
ALOX12 P18054 2/20 0.43
RECQL P46063 1/20 0.43
ATM Q13315 1/20 0.43
HIF1A Q16665 2/20 0.43
TP53 P04637 1/20 0.43
HSP90AA1 P07900 1/20 0.43
CASP1 P29466 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MAPK1 P28482 1/20 0.41
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL819617 0.92 ALDH1A1 (0.57) TDP1CYP3A4TSHRALDH1A1HSD17B10
SCHEMBL4165020 0.83 TDP1 (0.46) TDP1CYP3A4TSHRALDH1A1HSD17B10
Hydrochloric Acid SCHEMBL8189467 0.81 TDP1 (0.45) TDP1CYP3A4TSHRALDH1A1HSD17B10
Alcohol SCHEMBL6565108 0.81 TDP1 (0.45) TDP1CYP3A4TSHRALDH1A1HSD17B10
Hydrochloric Acid SCHEMBL10535811 0.81 TDP1 (0.45) TDP1CYP3A4TSHRALDH1A1HSD17B10
SCHEMBL28765035 0.79 TDP1 (0.43) TDP1CYP3A4TSHRALDH1A1HSD17B10
SCHEMBL10889923 0.78 ALDH1A1 (0.45) TDP1CYP3A4TSHRALDH1A1HSD17B10
SCHEMBL28766902 0.78 CSNK1E (0.45) TDP1ALDH1A1SMN1; SMN2MAPK1MEN1
SCHEMBL937251 0.77 TDP1 (0.44) TDP1CYP3A4TSHRALDH1A1HSD17B10
SCHEMBL4594822 0.77 ALDH1A1 (0.48) CYP3A4ALDH1A1HSD17B10LMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114507164-A Gemini surfactant, preparation method, composition and application thereof 中国石油天然气股份有限公司 2022-05-17 CN claimed
US-20040082486-A1 Molybdenum-containing lubricant additive compositions and processes for making and using same ETHYL CORPORATION 2004-04-29 US claimed
US-6645921-B2 Reaction product of fatty oil, diamine, and molybdenum source; free of organic solvents, carbon disulfide, sulfur and phosphorus compounds; internal combustion engines for automobiles and trucks ETHYL CORPORATION 2003-11-11 US claimed
US-20030171226-A1 Molybdenum-containing lubricant additive compositions, and processes for making and using same ETHYL CORPORATION 2003-09-11 US claimed
CN-116969845-A Dicyanoethyl tertiary amine hydrogenation method for reducing polycondensate content 万华化学集团股份有限公司 2023-10-31 CN disclosed
CN-110952077-B Method for forming metal film 株式会社FLOSFIA 2022-09-13 CN disclosed
CN-114507164-A Gemini surfactant, preparation method, composition and application thereof 中国石油天然气股份有限公司 2022-05-17 CN disclosed
EP-2990503-B1 METHOD OF FORMING METAL FILM FLOSFIA INC (JP) 2022-01-12 EP disclosed
CN-107428891-B Curable composition 施敏打硬株式会社 2021-04-20 CN disclosed
CN-105392845-B Photocurable composition 思美定株式会社 2020-10-20 CN disclosed
CN-110952077-A Method for forming metal film 株式会社FLOSFIA 2020-04-03 CN disclosed
CN-105386008-B Method for forming metal film 株式会社FLOSFIA 2020-01-21 CN disclosed
US-5654359-A INK RECEPTIVITY; WATERPROOFING SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1997-08-05 US disclosed
EP-0399519-B1 Potentiating cell-mediated immunity utilizing polyamine derivatives MERRELL PHARMA INC (US) 1996-08-07 EP disclosed
EP-0662829-A1 POLYAMINE DERIVATIVES AS ANTI-CYTOMEGALOVIRAL AGENTS MERRELL PHARMACEUTICALS INC. (US) 1995-07-19 EP disclosed
EP-0634524-A1 Paper coating composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1995-01-18 EP disclosed
WO-1994007480-A1 POLYAMINE DERIVATIVES AS ANTI-CYTOMEGALOVIRAL AGENTS MERRELL DOW PHARMACEUTICALS INC. (US) 1994-04-14 WO disclosed
EP-0277635-B1 Novel polyamine derivatives MERRELL DOW PHARMA (US) 1994-01-05 EP disclosed
EP-0399519-A2 Potentiating cell-mediated immunity utilizing polyamine derivatives MERRELL PHARMACEUTICALS INC. (US) 1990-11-28 EP disclosed
EP-0277635-A2 Novel polyamine derivatives MERRELL DOW PHARMACEUTICALS INC. (US) 1988-08-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082486-A1 Molybdenum-containing lubricant additive compositions and processes for making and using same NOTUM, ALOX5, PHOSPHO1 TDP1 675/4885CYP3A4 1002/4885TSHR 4708/4885
US-20030171226-A1 Molybdenum-containing lubricant additive compositions, and processes for making and using same NOTUM, AMD1, FDFT1 TDP1 603/4885CYP3A4 1275/4885TSHR 4762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.